These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Chun KS; Kim SH; Song YS; Surh YJ Carcinogenesis; 2004 May; 25(5):713-22. PubMed ID: 14729583 [TBL] [Abstract][Full Text] [Related]
24. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Akundi RS; Candelario-Jalil E; Hess S; Hüll M; Lieb K; Gebicke-Haerter PJ; Fiebich BL Glia; 2005 Aug; 51(3):199-208. PubMed ID: 15800925 [TBL] [Abstract][Full Text] [Related]
25. Pharmacological and molecular characterization of the mechanisms involved in prostaglandin E2-induced mouse paw edema. Claudino RF; Kassuya CA; Ferreira J; Calixto JB J Pharmacol Exp Ther; 2006 Aug; 318(2):611-8. PubMed ID: 16644903 [TBL] [Abstract][Full Text] [Related]
26. The aminosteroid phospholipase C antagonist U-73122 (1-[6-[[17-beta-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione) potently inhibits human 5-lipoxygenase in vivo and in vitro. Feisst C; Albert D; Steinhilber D; Werz O Mol Pharmacol; 2005 May; 67(5):1751-7. PubMed ID: 15684042 [TBL] [Abstract][Full Text] [Related]
27. Specific roles of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide-induced fever and Fos expression in rat brain. Zhang YH; Lu J; Elmquist JK; Saper CB J Comp Neurol; 2003 Aug; 463(1):3-12. PubMed ID: 12811798 [TBL] [Abstract][Full Text] [Related]
28. Effect of cyclooxygenase inhibitors on the CRH-induced pituitary-adrenocortical activity during crowding stress. Bugajski J; Gadek-Michalska A; Bugajski AJ J Physiol Pharmacol; 2003 Mar; 54(1):99-108. PubMed ID: 12674222 [TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Milas L Am J Clin Oncol; 2003 Aug; 26(4):S66-9. PubMed ID: 12902859 [TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Foitzik T; Hotz HG; Hotz B; Wittig F; Buhr HJ Hepatogastroenterology; 2003; 50(52):1159-62. PubMed ID: 12846004 [TBL] [Abstract][Full Text] [Related]
31. Somatostatin-induced activation and up-regulation of N-methyl-D-aspartate receptor function: mediation through calmodulin-dependent protein kinase II, phospholipase C, protein kinase C, and tyrosine kinase in hippocampal noradrenergic nerve endings. Pittaluga A; Feligioni M; Longordo F; Arvigo M; Raiteri M J Pharmacol Exp Ther; 2005 Apr; 313(1):242-9. PubMed ID: 15608072 [TBL] [Abstract][Full Text] [Related]
32. 1-[6-[[(17beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122) selectively inhibits Kir3 and BK channels in a phospholipase C-independent fashion. Klose A; Huth T; Alzheimer C Mol Pharmacol; 2008 Nov; 74(5):1203-14. PubMed ID: 18682550 [TBL] [Abstract][Full Text] [Related]
33. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594 [TBL] [Abstract][Full Text] [Related]
34. The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity. Lee IO; Seo Y Anesth Analg; 2008 Mar; 106(3):972-7, table of contents. PubMed ID: 18292448 [TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-1 mediates the final stage of morphine-induced delayed cardioprotection in concert with cyclooxygenase-2. Jiang X; Shi E; Nakajima Y; Sato S; Ohno K; Yue H J Am Coll Cardiol; 2005 May; 45(10):1707-15. PubMed ID: 15893191 [TBL] [Abstract][Full Text] [Related]
36. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Belton OA; Duffy A; Toomey S; Fitzgerald DJ Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. Natale G; Lazzeri G; Lubrano V; Colucci R; Vassalle C; Fornai M; Blandizzi C; Del Tacca M Toxicol Appl Pharmacol; 2004 Feb; 195(1):62-72. PubMed ID: 14962506 [TBL] [Abstract][Full Text] [Related]
38. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells. Ferrera P; Arias C Neurochem Int; 2005 Dec; 47(8):589-96. PubMed ID: 16169124 [TBL] [Abstract][Full Text] [Related]